Heterogeneity and Prognostic Factors in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) exhibits profound heterogeneity at genetic, epigenetic, phenotypic and microenvironmental levels. Inter-patient heterogeneity reflects diverse aetiologies, including hepatitis B or C infection, alcohol-related injury and non-alcoholic fatty liver disease, each driving distinct mutational landscapes. Within individual tumours, subclonal populations co-exist and evolve under selective pressures such as immune surveillance and local hypoxia. This intra-tumour heterogeneity underpins variable clinical behaviour, influencing rates of vascular invasion, metastatic spread and resistance to systemic therapies. Established prognostic factors include tumour size, number of lesions, microvascular invasion, serum alpha-fetoprotein level and underlying liver function. More recently, molecular signatures—ranging from gene-expression subtypes to epigenetic modifications such as DNA methylation—have emerged as predictors of recurrence risk and survival. Integration of imaging, liquid biopsy and multi-omics profiling promises to refine risk stratification, enabling tailored surveillance and therapeutic strategies across diverse patient populations.

Research from Nature Portfolio

A multi-regional genomic study of resected HCC specimens has elucidated the spatial dynamics of tumour evolution, revealing that genetic similarity correlates with physical proximity within the liver. Phylogenetic reconstruction showed both early and late branching events, with metastatic nodules displaying accelerated diversification relative to primary sites. Co-existent driver mutations were identified in distinct sectors, suggesting opportunities for drug repositioning to target shared vulnerabilities. These findings highlight the necessity of multi-site sampling to capture the full spectrum of tumour diversity and support the development of personalised therapeutic regimens based on comprehensive molecular mapping.

Heterogeneity and Prognostic Factors in Hepatocellular Carcinoma publication trend

The graph below shows the total number of articles in heterogeneity and prognostic factors in hepatocellular carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

Intra-tumour heterogeneity: Variation in genetic, phenotypic or microenvironmental features among cells within a single tumour.

Transcriptomic subtype: A classification of tumours based on patterns of gene-expression profiles.

DNA methylation: An epigenetic modification involving the addition of a methyl group to DNA, often at CpG sites, affecting gene regulation.

Prognostic factor: A clinical or molecular characteristic that predicts the likely course or outcome of a disease.

References

1. Diagnostic and prognostic value of STAP1 and AHNAK methylation in peripheral blood immune cells for HBV-related hepatopathy. Frontiers in Immunology (2023).
2. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nature Communications (2017).
3. Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. National Science Review (2021).
4. The significance of intertumor and intratumor heterogeneity in liver cancer. Experimental & Molecular Medicine (2018).
5. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (2021).